These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33430312)

  • 1. Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
    Stemmer SM; Manojlovic NS; Marinca MV; Petrov P; Cherciu N; Ganea D; Ciuleanu TE; Pusca IA; Beg MS; Purcell WT; Croitoru AE; Ilieva RN; Natošević S; Nita AL; Kalev DN; Harpaz Z; Farbstein M; Silverman MH; Bristol D; Itzhak I; Fishman P
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
    Fishman P; Stemmer SM; Bareket-Samish A; Silverman MH; Kerns WD
    Purinergic Signal; 2023 Sep; 19(3):513-522. PubMed ID: 36781824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report.
    Ciurescu IA; Lencioni R; Stemmer SM; Farbstein M; Harpaz Z; Bareket-Samish A; Silverman MH; Fishman P
    Exp Ther Med; 2024 Jun; 27(6):263. PubMed ID: 38756903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
    Safadi R; Braun M; Francis A; Milgrom Y; Massarwa M; Hakimian D; Hazou W; Issachar A; Harpaz Z; Farbstein M; Itzhak I; Lev-Cohain N; Bareket-Samish A; Silverman MH; Fishman P
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1405-1415. PubMed ID: 34671996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
    El-Khoueiry AB; Meyer T; Cheng AL; Rimassa L; Sen S; Milwee S; Kelley RK; Abou-Alfa GK
    BMC Cancer; 2022 Apr; 22(1):377. PubMed ID: 35397508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
    Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M
    Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
    Etzion O; Bareket-Samish A; Yardeni D; Fishman P
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
    Ryoo BY; Palmer DH; Park SR; Rimassa L; Debashis Sarker ; Daniele B; Steinberg J; López B; Lim HY
    Clin Drug Investig; 2021 Sep; 41(9):795-808. PubMed ID: 34351608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.
    Cheon J; Kim H; Kim HS; Kim CG; Kim I; Kang B; Kim C; Jung S; Ha Y; Chon HJ
    Ther Adv Med Oncol; 2023; 15():17588359221148541. PubMed ID: 37705533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ; Lee HJ; Lee SH
    Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
    Kelley RK; Ryoo BY; Merle P; Park JW; Bolondi L; Chan SL; Lim HY; Baron AD; Parnis F; Knox J; Cattan S; Yau T; Lougheed JC; Milwee S; El-Khoueiry AB; Cheng AL; Meyer T; Abou-Alfa GK
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.
    Kudo M; Lim HY; Cheng AL; Chao Y; Yau T; Ogasawara S; Kurosaki M; Morimoto N; Ohkawa K; Yamashita T; Lee KH; Chen E; Siegel AB; Ryoo BY
    Liver Cancer; 2021 Jun; 10(3):275-284. PubMed ID: 34239813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.